Roche lifted the Swiss drugmaker’s 2019 sales target for the third time during the year, helped by newer medicines and as China bought more cancer drugs to treat a disease blamed for a quarter of the nation’s annual deaths.
Indivior Plc raised the company’s full-year 2019 forecasts as the embattled British drugmaker’s best-selling opioid addiction drug Suboxone fared better than expected in the face of competition from copycats.
Novo Nordisk’s sales forecast for 2019 was raised due to growing demand for obesity products and a new injectable treatment for diabetes, which is now the company’s growth engine as insulin sales decline.
Teva Pharmaceutical Industries reported a smaller-than-expected drop in second-quarter 2019 profit and said the chief financial officer was leaving the company.
Teva Pharmaceutical Industries posted a slightly smaller than expected drop in first-quarter 2019 profit and forecast a sharp rise in 2020 revenue from the company’s new migraine drug Ajovy.
Merck & Co. reported higher-than-expected Q1 profit on increased demand for vaccines and the cancer immunotherapy Keytruda, and raised the company’s 2019 earnings and revenue forecasts.
Pfizer beat Wall Street estimates for Q1 profit and slightly raised the company’s 2019 earnings forecast as the largest U.S. drugmaker reined in costs and recorded higher Ibrance and Prevnar sales.
Eli Lilly reported lower-than-expected first-quarter 2019 sales for the company’s top-selling diabetes drug Trulicity, due in part to patient affordability programs.
Novartis raised the company’s 2019 profit target, striking an upbeat tone over a legal fight with peer and partner Amgen and on the safety of a key gene therapy that could win approval in May 2019.
Allergan Plc’s experimental add-on treatment for depression failed three late-stage studies, casting doubts over the company’s drug pipeline and sending the Botox maker’s shares down nearly 4 percent.